CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL

The goal of this clinical trial is to test CD19-7×19 CAR-T cells combined with Tislelizumab in refractory and relapsed diffuse large B lymphoma. The main question\[s\] it aims to answer are: question 1：What is the safety of CD19-7×19 CAR-T cells combined with Tislelizumab in the treatment of relapsed or refractory diffuse large B-cell lymphoma. question 2：What is the efficacy of CD19-7×19 CAR-T cells combined with Tislelizumab in the treatment of relapsed or refractory diffuse large B-cell lymphoma. Participants will be asked to receive clinical evaluation before CAR-T, including physical e

Trial Details

NCT ID
NCT05659628
Phase
PHASE1
Sponsor
Ningbo No. 1 Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • CD19-7×19 CAR-T combined with Tislelizumab
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142
  • Ningbo, Zhejiang, China|29.87819,121.54945

Key Eligibility Criteria

  • Age ≥ 18, upper limit 75, male or female;
  • ECOG score 0-3;
  • Histologically confirmed diffuse large B-cell lymphoma (DLBCL) \[diagnostic criteria according to WHO 2008\];
  • CD19 positive (immunohistochemistry or flow cytometry).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →